Health Care & Life Sciences » Biotechnology | Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
75,722.00
149,054.00
517,466.00
421,748.00
292,690.00
270,138
Total Accounts Receivable
296.00
410.00
4,054.00
8,629.00
13,133.00
5,096
Other Current Assets
1,640.00
1,794.00
6,761.00
9,748.00
5,367.00
13,334
Total Current Assets
77,658.00
151,258.00
528,281.00
440,125.00
311,190.00
288,568
Net Property, Plant & Equipment
3,744.00
3,794.00
4,539.00
6,207.00
30,762.00
28,718
Total Investments and Advances
-
-
-
1,543.00
1,543.00
1,543
Other Assets
389.00
579.00
394.00
406.00
552.00
2,705
Total Assets
81,791.00
155,631.00
548,285.00
448,281.00
344,047.00
321,534
Accounts Payable
348.00
1,096.00
1,894.00
4,063.00
2,237.00
Income Tax Payable
-
-
46,437.00
-
-
Other Current Liabilities
13,475.00
18,719.00
31,037.00
34,678.00
48,744.00
Total Current Liabilities
13,823.00
19,815.00
79,368.00
38,741.00
50,981.00
Deferred Taxes
-
-
15,071.00
-
-
Other Liabilities
9,942.00
50,611.00
35,711.00
17,965.00
27,864.00
Total Liabilities
23,765.00
70,426.00
115,079.00
56,706.00
78,845.00
Common Equity (Total)
58,026.00
85,205.00
433,206.00
391,575.00
265,202.00
Total Shareholders' Equity
58,026.00
85,205.00
433,206.00
391,575.00
265,202.00
Total Equity
58,026.00
85,205.00
433,206.00
391,575.00
265,202.00
Liabilities & Shareholders' Equity
81,791.00
155,631.00
548,285.00
448,281.00
344,047.00

About Five Prime Therapeutics

View Profile
Address
111 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.fiveprime.com
Updated 07/08/2019
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.